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Disease-Causing Polymorphisms in the
Spectrum of Long QT Syndrome Mutations*
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(ong QT syndrome (LQTS) exemplifies many of the
omplexities of the genetic basis of disease. Mutations of
ifferent genes can cause a similar phenotype. Identical
utations can give rise to variable phenotypes. Obvious
henotypes can elude detection of an underlying genetic
bnormality. Common, “benign” genetic variations can cause
isease.
After discovery that mutations in several genes could
ause congenital LQTS (1–4), and that many individuals
ith these mutations displayed negligible QT prolongation
5,6) (“silent LQTS”), it was postulated that drug-,
radycardia-, or electrolyte-induced “acquired” LQTS
ight represent unmasking of the LQTS phenotype in
eople with silent underlying LQTS mutations. As Roden
7) has articulated in the repolarization reserve hypothesis,
ultiple challenges to the myocyte’s repolarization mecha-
isms may be required to produce clinical QT-interval
rolongation. Studies seeking confirmation of a genetic
redisposition revealed LQTS mutations in a minority of
atients with acquired LQTS, as well as a disproportion-
tely high prevalence of certain LQTS gene polymorphisms
8–15).
See page 812
One of these genetic variants was the KCNE1 polymor-
hism D85N, which Paulussen et al. (13) found in 5% of
atients presenting with torsades de pointes after receiving
T-interval–prolonging drugs (but in 0% of controls in that
tudy) (13). This polymorphism has been detected in 0.7%
f an Asian population (16). The KCNE1 polymorphism
ncodes the beta-subunit of the IKs channel (17) and also
nteracts with KCNH2, which encodes the alpha-subunit of
he IKr channel (18), although KCNE1/KCNH2 interac-
ions in native cardiomyocytes are not firmly established.
utations in KCNE1 can cause LQT5.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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upport from CardioDx, Cambridge Heart, Inc., and St. Jude Medical.In this issue of the Journal, Nishio et al. (19) report
nding 23 D85N heterozygotes and 1 homozygote among
17 LQTS probands screened, to yield an allele frequency
f 3.9%, compared with 0.81% in healthy controls. After
xcluding 7 probands with additional mutations in LQTS
enes and 3 women with “predisposing factors” (drug
xposure, electrolyte disorder, or bradycardia), the allele
requency was 2.1%. The LQTS probands with the D85N
ariant had a milder phenotype than probands with other
QTS mutations: shorter mean QT interval corrected for
eart rate (QTc) (507.9  9.2 ms vs. 540.6  6.1 ms) and
lder age at onset of symptoms (35.5  10.4 years vs. 21.0
ears). Nevertheless, 6 of the 13 patients with only D85N
etected had syncope and/or documented torsades de
ointes and QTc ranged as high as 650 ms. Based on these
ompelling findings, D85N appears to be a disease-causing
enetic variant.
Nishio et al. (19) further demonstrated in mammalian cells
hat D85N reduced KCNQ1-encoded currents by 28% (pre-
ious experiments in Xenopus oocytes had shown a 50%
eduction) (20). Moreover, D85N reduced KCNH2-encoded
urrents by 31% to 36%. Thus, the investigators reason,
utations in KCNE1 may cause clinical features similar to
hose seen in LQT2. In fact, 3 of the D85N carriers in the
urrent study had sinus bradycardia (as can be seen in LQT2).
The requirement for multiple repolarization challenges to
nmask the phenotype in a substantial subset of the D85N
ubjects, as well as the older age of onset of symptoms and
he shorter mean QTc interval as compared with probands
ith other LQTS mutations, point to a generally milder
QTS phenotype in D85N carriers. On the other hand,
85N is likely clinically important, especially in older
ndividuals, who remain at risk of torsades de pointes (21)
nd whose exposure to bradycardia, electrolyte disorders,
nd QT-interval–prolonging drugs increases with age.
It was long assumed that polymorphisms were benign—
fter all, they are relatively prevalent in healthy populations.
e now know from other studies that polymorphisms can
orsen or improve the phenotype in the presence of
isease-causing mutations (22,23), or even, as Tan et al.
24) showed, cause disease in the presence of a second
splicing) genetic variation. The current study (19) shows
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August 25, 2009:820–1 Disease-Causing Polymorphismshat the D85N polymorphism can itself cause disease and
hould more appropriately be classified as a mutation.
It is becoming increasingly clear that we cannot define
ealth or disease by mutation status alone. An asymptom-
tic individual without QT interval prolongation, found
uring family screening to carry a known “disease-causing”
utation, is at much lower risk than a patient who presents
ith syncope, torsades de pointes, and marked QT interval
rolongation in the absence of drug exposure or electrolyte
isturbance, and whose genetic testing reveals only “benign”
olymorphisms. Even as genetic testing becomes more
ophisticated, there is still a critical role for clinical evalua-
ion and risk profiling.
This is not to minimize the value of genetic testing.
nowledge of gene status in LQTS family members with a
orderline phenotype, and determination of LQTS subtype
n patients with a clear phenotype, directly inform decisions
bout evaluation and follow-up. Results of genetic evalua-
ion, appropriately incorporated into a more comprehensive
linical evaluation and risk assessment, can save lives,
mprove quality of life, reduce inappropriate and potentially
isky interventions, and conserve medical resources. Fur-
hermore, if widespread genetic surveys become practical
ithin the normal-phenotype population, awareness of
nderlying polymorphisms, such as D85N, could point to
otential repolarization vulnerability and guide therapy
way from known QT-interval–prolonging drugs. Addi-
ional well-executed studies like that of Nishio et al. (19)
ay advance us further in that direction. Until then, the
linician must resort to standard strategies such as monitor-
ng the QT interval and avoiding combinations of QT-
nterval–prolonging and electrolyte-disturbing drugs.
eprint requests and correspondence: Dr. Elizabeth S. Kauf-
an, Heart and Vascular Research Center, Hamann 3rd Floor,
etroHealth Campus, Case Western Reserve University, 2500
etroHealth Drive, Cleveland, Ohio 44109-1998. E-mail:
kaufman@metrohealth.org.
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